natgillin/translations-raw huggingface dataset:
In patients with a poor haemoglobin response to epoetins, alternative explanations for the poor response should be considered (see sections 4.2 and 5.1).
U bolesnika sa slabim hemoglobinskim odgovorom na epoetine potrebno je razmotriti druga moguća objašnjenja slabog odgovora (vidjeti dijelove 4.2 i 5.1).
In patients with a poor haemoglobin response to epoetins, alternative explanations for the poor response should be considered (see sections 4.2 and 5.1).
U bolesnika sa slabim odgovorom hemoglobina na epoetine potrebno je razmotriti druga moguća objašnjenja za slabi terapijski odgovor (vidjeti dijelove 4.2 i 5.1).
In patients with a poor haemoglobin response to Retacrit, alternative explanations for the poor response should be considered (see sections 4.4 and 5.1).
U bolesnika sa slabim odgovorom hemoglobina na Retacrit, potrebno je razmotriti druga moguća objašnjenja za slabi odgovor (vidjeti dijelove 4.4 i 5.1).
In patients with a poor haemoglobin response to Silapo, alternative explanations for the poor response should be considered (see sections 4.4 and 5.1).
U bolesnika sa slabim odgovorom hemoglobina na Silapo, potrebno je razmotriti druga moguća objašnjenja za slabi odgovor (vidjeti dijelove 4.4 i 5.1).
In patients with a predisposing risk due to previous prolonged, systemic aminoglycoside therapy it may be necessary to consider renal and audiological assessment before initiating TOBI Podhaler therapy.
U bolesnika s predisponirajućim rizikom uzrokovanim prethodnom produljenom sistemskom terapijom aminoglikozidima moglo bi biti potrebno razmotriti bubrežne i audiološke pretrage prije početka terapije TOBI Podhalerom.
In patients with a recent low- trauma hip fracture, a loading dose of 50 000 to 125 000 IU of vitamin D given orally or via the intramuscular route is recommended prior to the first zoledronic acid infusion.
U bolesnika s nedavnim prijelomom kuka nakon manje traume, preporučuje se prije prve infuzije zoledronatne kiseline dati udarnu dozu od 50 000 do 125 000 IU vitamina D peroralnim ili intramuskularnim putem.
In patients with a recent low-trauma hip fracture, a loading dose of 50 000 to 125 000 IU of vitamin D given orally or via the intramuscular route is recommended prior to the first Aclasta infusion.
U bolesnika s nedavnim prijelomom kuka nakon manje traume, preporučuje se prije prve infuzije Aclaste dati udarnu dozu od 50 000 do 125 000 IU vitamina D peroralnim ili intramuskularnim putem.
In patients with a recent low-trauma hip fracture, a loading dose of 50 000 to 125 000 IU of vitamin D given orally or via the intramuscular route is recommended prior to the first zoledronic acid infusion.
U bolesnika s nedavnim prijelomom kuka nakon manje traume, preporučuje se prije prve infuzije zoledronatne kiseline dati udarnu dozu od 50 000 do 125 000 IU vitamina D peroralnim ili intramuskularnim putem.
In patients with a recent low-trauma hip fracture, it is recommended to give the zoledronic acid infusion at least two weeks after hip fracture repair (see section 5.1).
U bolesnika s nedavnim prijelomom kuka nakon slabe traumei preporučuje se primjena infuzije zoledronatne kiseline najmanje dva tjedna nakon oporavka prijeloma kuka (vidjeti dio 5.1).
In patients with achlorhydria, such as certain AIDS patients and patients on acid secretion suppressors (e.g.
U bolesnika s aklorhidrijom, kao što su bolesnici s AIDS-om i bolesnici koji primaju supresore lučenja želučane kiseline (npr.
In patients with acromegaly, Signifor is given as a long-acting injection into the buttock muscle every four weeks.
U bolesnika koji boluju od akromegalije, Signifor se primjenjuje kao dugodjelujuća injekcija u mišić stražnjice svaka četiri tjedna.
In patients with acromegaly, the most common side effects (seen in more than 1 patient in 10) are hyperglycaemia, diabetes, diarrhoea and cholelithiasis.
U bolesnika s akromegalijom, najčešće nuspojave (mogu se javiti u više od 1 na 10 osoba) su hiperglikemija, dijabetes, proljev i kolelitijaza.
In patients with ACS, it is recommended that renal function is also checked one month after initiating the treatment with ticagrelor, paying special attention to patients ≥75 years, patients with moderate/severe renal impairment and those receiving concomitant treatment with an angiotensin receptor blocker (ARB).
U bolesnika s akutnim koronarnim sindromom preporučeno je da se bubrežna funkcija također provjeri mjesec dana nakon započinjanja liječenja tikagrelorom, s posebnom pozornošću prema bolesnicima ≥ 75 godina, bolesnicima s umjerenim/teškim oštećenjem bubrega i onima koji istodobno primaju terapiju blokatorima angiotenzinskih receptora.
In patients with acute coronary syndrome (ACS) who are managed with PCI, premature discontinuation of any antiplatelet agent, including Efient, could result in an increased risk of thrombosis, myocardial infarction or death due to the patient’s underlying disease.
U bolesnika s akutnim koronarnim sindromom (engl. acute coronary syndrome, ACS) podvrgnutih PCI-u, prerani prekid primjene bilo kojeg antitrombocitnog lijeka, uključujući Efient, može povećati rizik od tromboze, infarkta miokarda ili smrti kao komplikacije bolesnikove osnovne bolesti.
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT.
U bolesnika s akutnim infarkta miokarda sa ST elevacijom (STEMI), sigurnost primjene i djelotvornost klopidogrela procijenjena je u 2 randomizirane, dvostruko slijepe, placebom kontrolirane studije, CLARITY i COMMIT.
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT.
U bolesnika s akutnim infarkta miokarda sa ST elevacijom (STEMI), sigurnost primjene i djelotvornost klopidogrela procijenjena je u 2 randomizirane, dvostrukoslijepe, placebom kontrolirane studije, CLARITY i COMMIT.
In patients with acute thrombotic disease, both the incremental increase in protein C plasma levels as well as half-life may be considerably reduced.
Kod pacijenata s akutnom trombotskom bolešću i inkrementalni porast razine proteina C u plazmi i poluvijek mogu biti značajno smanjeni.
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
U pacijenata s uznapredovalom bolešću ili cirozom jetre, prekid liječenja se ne preporučuje jer egzacerbacija hepatitisa nakon liječenja može dovesti do dekompenzacije jetre.
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
U pacijenata s uznapredovalom bolešću jetre ili cirozom jetre ne preporučuje se prekid liječenja, jer egzacerbacija hepatitisa nakon liječenja može dovesti do dekompenzacije jetre.
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
U pacijenata s uznapredovalom bolešću jetre ili cirozom jetre, ne preporučuje se prekidati liječenje jer egzacerbacija hepatitisa nakon liječenja može dovesti do dekompenzacije jetre.
In patients with advanced phase CML or Ph+ ALL, complete blood counts should be performed weekly for the first 2 months, and then monthly thereafter, or as clinically indicated.
Tijekom prva 2 mjeseca liječenja bolesnika u uznapredovaloj fazi KML ili Ph+ ALL potrebno je svakog tjedna raditi kompletnu krvnu sliku; nakon tog razdoblja kompletna krvna slika može se raditi jedanput mjesečno ili prema kliničkoj indikaciji.
In patients with aHUS, their kidney and blood cells, including platelets, can be inflamed which can lead to low blood counts (thrombocytopenia and anaemia), reduced or lost kidney function, blood clots, tiredness and difficulty in functioning.
U bolesnika s atipičnim hemolitičko-uremijskim sindromom može doći do upalom posredovanog oštećenja bubrega i krvnih stanica, uključujući krvne pločice, što može dovesti do sniženog broja krvnih stanica (trombocitopenije i anemije), slabljenja ili gubitka funkcije bubrega, stvaranja krvnih ugrušaka, umora i otežanog funkcioniranja.
In patients with ALK- positive NSCLC, an abnormal form of ALK is produced that stimulates the cancer cells to divide and grow in an uncontrolled fashion.
U bolesnika s ALK-pozitivnim NSCLC-om stvara se abnormalan oblik ALK-a koji stimulira stanice raka na nekontroliranu diobu i rast.
In patients with Alzheimer’s dementia or dementia due to Parkinson’s disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a chemical that allows nerve cells to communicate with each other).
U bolesnika s Alzheimerovom demencijom ili demencijom uzrokovanom Parkinsonovom bolešću, određene živčane stanice u mozgu odumiru, što ima za posljedicu nisku koncentraciju neurotransmitera acetilkolina (tvari koja omogućuje živčanim stanicama da međusobno komuniciraju).
In patients with Alzheimer’s dementia or dementia due to Parkinson’s disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other).
U bolesnika s Alzheimerovom demencijom ili demencijom uslijed Parkinsove bolesti, određene živčane stanice odumiru u mozgu, što dovodi do niskih razina neurotransmitera acetilkolina (tvari koja živčanim stanicama omogućava međusobnu komunikaciju).
In patients with Alzheimer’s dementia or dementia due to Parkinson’s disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other).
U bolesnika s Alzheimerovom demencijom ili demencijom uzrokovanom Parkinsonovom bolešću, određene živčane stanice u mozgu odumiru, što ima za posljedicu nisku koncentraciju neurotransmitera acetilkolina (tvari koja omogućuje živčanim stanicama da međusobno komuniciraju).
In patients with Alzheimer’s dementia, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other).
U bolesnika koji boluju od Alzheimerove demencije, određene živčane stanice u mozgu umiru, što rezultira niskim razinama neurotransmitera acetilkolina (tvari koja omogućuje živčanim stanicama međusobnu komunikaciju).
In patients with Alzheimer’s dementia, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other).
U bolesnika s Alzheimerovom demencijom, određene živčane stanice u mozgu odumiru, što ima za posljedicu nisku koncentraciju neurotransmitera acetilkolina (tvari koja omogućuje živčanim stanicama da međusobno komuniciraju).
In patients with Alzheimer’s disease, inhibition of AChE in CSF by oral rivastigmine was dose-dependent up to 6 mg given twice daily, the highest dose tested.
U bolesnika s Alzheimerovom bolešću inhibicija AChE u cerebrospinalnoj tekućini oralnim rivastigminom bila je ovisna o dozi sve do 6 mg dva puta na dan, što je bila najviša ispitivana doza.
In patients with Alzheimer’s disease, inhibition of AChE in CSF by oral rivastigmine was dose-dependent up to 6 mg given twice daily, the highest dose tested.
U bolesnika s Alzheimerovom bolešću, inhibicija AChE u cerebrospinalnoj tekućini oralnim rivastigminom bila je ovisna o dozi sve do 6 mg dva puta na dan, što je bila najviša ispitivana doza.
In patients with Alzheimer’s disease, inhibition of AChE in CSF by rivastigmine was dose-dependent up to 6 mg given twice daily, the highest dose tested.
U bolesnika s Alzheimerovom bolešću inhibicija AChE u cerebrospinalnoj tekućini rivastigminom bila je ovisna o dozi sve do 6 mg dva puta na dan, što je bila najviša ispitivana doza.
In patients with Alzheimer’s disease, inhibition of AChE in CSF by rivastigmine was dose-dependent up to 6 mg given twice daily, the highest dose tested.
U bolesnika s Alzheimerovom bolešću inhibicija AChE-a u cerebrospinalnoj tekućini rivastigminom bila je ovisna o dozi sve do 6 mg dva puta na dan, što je bila najviša ispitivana doza.
In patients with Alzheimer’s disease, inhibition of AChE in CSF by rivastigmine was dose-dependent up to 6 mg given twice daily, the highest dose tested.
U bolesnika s Alzheimerovom bolešću, inhibicija AChE u cerebrospinalnoj tekućini rivastigminom bila je ovisna o dozi sve do 6 mg dva puta na dan, što je bila najviša ispitivana doza.
In patients with an activated renin-angiotensin system (such as volume- and/or salt-depleted patients receiving high doses of diuretics) who are receiving angiotensin receptor blockers, symptomatic hypotension may occur.
U bolesnika s aktiviranim renin- angiotenzinskim sustavom (poput bolesnika sa smanjenim volumenom tekućine i/ili sniženom razinom soli na visokim dozama diuretika) koji primaju blokatore angiotenzinskih receptora, može doći do simptomatske hipotenzije.
In patients with an adjusted creatinine clearance of 50–70 ml/min/1.73 m2, administration should commence at a dose of 100 mg twice daily in patients with type 1 Gaucher disease and at a dose of 200 mg twice daily (adjusted for body surface area in patients below the age of 12) in patients with Niemann-Pick type C disease.
Kod bolesnika s prilagođenim klirensom kreatinina od 50–70 ml/min/1,73 m2, primjenu treba početi s dozom od 100 mg dvaput dnevno u bolesnika s Gaucherovom bolesti tipa 1, te dozom od 200 mg dvaput dnevno (prilagođeno površini tijela u bolesnika mlađih od 12 godina) u bolesnika s Niemann-Pickovom bolesti tipa C.
In patients with an already manifest diabetes mellitus, the anti-diabetic therapy might require adjustment when somatropin treatment is initiated.
U bolesnika s već manifestnom šećernom bolešću moguća je prilagodba antidijabetičke terapije prilikom započinjanja terpaije somatropinom.
In patients with an ejection fraction below the institution’s lower limit of normal, cardiac consultation as well as treatment interruption or discontinuation should be considered.
Kod bolesnika s ejekcijskom frakcijom ispod donje granice normale ustanove, potrebno je razmotriti savjetovanje s kardiologom kao i privremeni ili trajni prekid liječenja.
In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at Week 36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency was reduced to every other week, or in whom treatment was withdrawn (see Table 15).
Među bolesnicima koji su u 12. tjednu ostvarili barem djelomičan odgovor na liječenje lijekom Humira u dozi od 40 mg svaki tjedan, stopa HiSCR-a zabilježena u 36. tjednu bila je veća u onih bolesnika koji su nastavili primati lijek Humira svaki tjedan nego u bolesnika kojima je učestalost doziranja smanjena na jednom svaki drugi tjedan ili onih kojima je liječenje ukinuto (vidjeti Tablicu 15).
In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at Week 36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency was reduced to every other week, or in whom treatment was withdrawn (see Table 17).
Među bolesnicima koji su u 12. tjednu ostvarili barem djelomičan odgovor na liječenje lijekom Humira u dozi od 40 mg svaki tjedan, stopa HiSCR-a zabilježena u 36. tjednu bila je veća u onih bolesnika koji su nastavili primati lijek Humira svaki tjedan nego u bolesnika kojima je učestalost doziranja smanjena na jednom svaki drugi tjedan ili onih kojima je liječenje ukinuto (vidjeti Tablicu 17).
In patients with atopic dermatitis, improvement of skin lesions during treatment with tacrolimus ointment was associated with reduced Fc receptor expression on Langerhans cells and a reduction of their hyperstimulatory activity towards T cells.
U bolesnika s atopijskim dermatitisom poboljšanje kožnih lezija tijekom liječenja takrolimus mašću bilo je povezano sa smanjenim izražavanjem Fc receptora na Langerhansovim stanicama i smanjenjem njihovog hiperstimulacijskog djelovanja na T stanice.
In patients with atrial fibrillation and conditions that warrant mono or dual antiplatelet therapy, a careful assessment of the potential benefits against the potential risks should be made before combining this therapy with Eliquis.
U bolesnika s fibrilacijom atrija i stanjima koja iziskuju monoterapiju ili dvojnu terapiju antitrombocitnim lijekovima potrebno je provesti podrobnu procjenu potencijalnih koristi i potencijalnih rizika prije kombiniranja takve terapije s lijekom Eliquis.
In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg.
U bolesnika s atrijskom fibrilacijom klopidogrel se primjenjuje u dozi od 75 mg jednom dnevno.
In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg.
U bolesnika s fibrilacijom atrija, klopidogrel se daje u jednokratnoj dnevnoj dozi od 75 mg.
In patients with baseline cytopenias, sustained hematologic improvement was: platelets 77.1% versus 42.9%; hemoglobin 84.3% versus 45.5% for ibrutinib and chlorambucil respectively.
U bolesnika koji su na početku imali citopeniju, održano hematološko poboljšanje bilo je: trombociti 77,1% naspram 42,9%; hemoglobin 84,3% naspram 45,5% za ibrutinib odnosno klorambucil.
In patients with BL VL1
U pacijenata s BL VL1
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30 – 60 ml/min, the following zoledronic acid dose is recommended (see also section 4.4):
U bolesnika s metastazama u kostima koji prije početka liječenja imaju blago do umjereno oštećenje funkcije bubrega, definirano u ove populacije kao klirens kreatinina od 30 do 60 ml/min, preporučuje se sljedeća doza zoledronatne kiseline (vidjeti također dio 4.4):
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30–60 ml/min, reduced Zoledronic Acid Hospira doses are recommended (see also section 4.4).
U bolesnika s koštanim metastazama koji prije početka terapije imaju blago do umjereno oštećenje bubrega koje se za ovu populaciju definira kao CLcr od 30 do 60 ml/min, preporučuje se sljedeća doza zoledronatne kiseline (vidjeti također dio 4.4):
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30–60 ml/min, the following zoledronic acid dose is recommended (see also section 4.4):
U bolesnika s koštanim metastazama koji prije početka terapije imaju blago do umjereno oštećenje bubrega koje se za tu populaciju definira kao CLcr od 30 do 60 ml/min, preporučuje se sljedeća doza zoledronatne kiseline (vidjeti također dio 4.4):
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30–60 ml/min, the following Zoledronic acid Teva dose is recommended (see also section 4.4):
U bolesnika s metastazama u kostima koji prije početka liječenja imaju blago do umjereno oštećenje funkcije bubrega, koje se u ove populacije definira kao klirens kreatinina od 30 do 60 ml/min, preporučuje se sljedeća doza Zoledronatne kiseline Teva (vidjeti također dio 4.4):
In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30–60 ml/min, the following Zometa dose is recommended (see also section 4.4):
U bolesnika s metastazama u kostima koji prije početka liječenja imaju blago do umjereno oštećenje funkcije bubrega, koje se u ove populacije definira kao CLcr od 30 do 60 ml/min, preporučuje se sljedeća doza Zomete (vidjeti također dio 4.4):
In patients with BRAF V600K mutation positive metastatic melanoma (n=16) the response rate was 13% (95% CI: 0.0, 28.7) with a median duration of response of 5.3 months (95% CI: 3.7, 6.8).
U bolesnika s BRAF V600K pozitivnim metastatskim melanomom (n=16) stopa odgovora je bila 13% (95% CI: 0,0; 28,7), s medijanom trajanja odgovora od 5,3 mjeseci (95% CI: 3,7; 6,8).
In patients with BRVO, one or more branches of the main blood vessel that transports blood away from the retina is blocked.
U bolesnika s BRVO, jedan ili više ogranaka glavne krvne žile koja odnosi krv iz mrežnice je blokiran.
In patients with CAPS, the body produces excessive amounts of IL-1 beta.
Kod bolesnika s CAPS-om tijelo proizvodi prekomjerne količine IL-1 beta.
In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension, therapy with beta-blockers should be critically assessed and the therapy with other active substances should be considered.
Kod bolesnika sa kardiovaskularnim bolestima (npr. koronarna bolest srca, Prinzmetalova angina i zatajenje srca) i hipotenzijom, potrebno je kritički procijeniti terapiju beta blokatorima i uzeti u obzir terapiju drugim djelatnim tvarima.
In patients with chronic liver disease treated with eltrombopag there was an association between TEE and platelet counts ≥ 200,000µl.
Kod bolesnika s kroničnim oštećenjem jetre liječenih eltrombopagom, postoji povezanost između TED i broja trombocita ≥ 200 000/µl.
In patients with chronic renal failure and clinically evident ischemic heart disease or congestive heart failure, maintenance haemoglobin concentration should not exceed the upper limit of the target haemoglobin concentration.
Kod bolesnika s kroničnim zatajenjem bubrega i klinički evidentnom ishemičnom bolesti srca ili kongestivnim zatajenjem srca, održana koncentracija hemoglobina ne bi trebala prijeći gornju granicu ciljne koncentracije hemoglobina.
In patients with chronic renal failure undergoing haemodialysis, the elimination half-life of epoetin theta is 6 hours after single dosing and 4 hours in steady state after repeated intravenous administration of 40 IU/kg body weight epoetin theta three times weekly.
Kod bolesnika s kroničnim zatajenjem bubrega koji su na hemodijalizi, poluvrijeme eliminacije epoetina theta je 6 sati nakon jednokratne doze i 4 sata u stanju dinamičke ravnoteže nakon ponovljene intravenske primjene epoetina theta od 40 IU/kg tjelesne težine, tri puta tjedno.
In patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Abseamed by the intravenous route is preferable.
U bolesnika s kroničnim zatajenjem bubrega u kojih je rutinski dostupan intravenski pristup (bolesnici na hemodijalizi) preferira se primjerna lijeka Abseamed intravenskim putem.
In patients with chronic renal failure, anaemia can be caused by a lack of erythropoietin.
Kod bolesnika s kroničnim zatajenjem bubrega anemiju može uzrokovati nedostatak eritropoetina.
In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the haemoglobin concentration range as recommended in section 4.2. In clinical trials, an increased risk of death and serious cardiovascular events was observed when ESAs were administered to achieve a haemoglobin concentration level of greater than 12 g/dl (7.5 mmol/l).
U bolesnika s kroničnim zatajenjem bubrega, održavana koncentracija hemoglobina ne smije prekoračiti gornju granicu raspona koncentracije hemoglobina kao što je preporučeno u dijelu 4.2. U kliničkim ispitivanjima je opažen povećani rizik od smrti i ozbiljnih kardiovaskularnih događaja kada su primjenjivani lijekovi za stimulaciju eritropoeze za postizanje vrijednosti koncentracije hemoglobina veće od 12 g/dl (7,5 mmol/l).